![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Eisai to Transfer Sales Operations of Inhibace to Chugai
Eisai to Transfer Sales Operations of Inhibace to Chugai
Eisai has agreed with Chugai Pharmaceutical to transfer the sales operations
of Inhibace, an antihypertensive agent first synthesized by Roche. Under the
terms of the agreement, Chugai will become a sole distributor of Inhibace as
of April 1. Inhibace is a long-acting ACE inhibitor for controlling blood pressure.
Currently, Chugai is manufacturing the product, and Eisai is solely distributing
it in Japan.
Japan
Corporate News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct